A Protection Strategy Substantially Enhances Rate and Enantioselectivity
COMMUNICATIONS
PDA detector. A pressure of 0.5 psi was applied for 5 s for
the injection. The background electrolyte contained triethyl-
ACHTREUNGammonium phosphate (50 mM, pH 3.0). A voltage of 30 kV
was started by the addition of Ade-TA solution (2 mL) and
stirred with a magnetic stirrer bar. After 19 h, the enantio-
meric excess reached 97% ee at a conversion of 55%. The
proteins of the reaction mixture were removed after addi-
tion of ice-cold acetone (100 mL) and incubation for 4 h at
48C. After evaporation of acetone, the amine was extracted
as described above. The yield of 1f was 42%. 1H- and
13CNMR spectra confirmed the structure of 1f.
was applied for four minutes for separation, the compounds
1c and 1f were detected at 190 nm and 1a, 1b and 1d at
200 nm. For the measurement of the concentration of 1a
and 1e, an indirect detection method was developed. The
compounds had to be extracted from a sample (100 mL) by
the addition of NaOH (50 mL 15M) and chloroform
(300 mL). The chloroform phase (200 mL) was subsequently
extracted with phosphoric acid (5 mM). This solution was in-
jected into the capillary (5 s, 1 psi). The background electro-
lyte contained m-xylenediamine phosphate (10 mM, pH 2.5).
The capillary had a total length of 40 cm, and an effective
length of 30 cm. A voltage of 15 kV was applied for 6 min
for separation.
1f: 1H NMR (300 MHz, CDCl3): d=1.42 (s, 9H, CH3),
1.60–1.68 (m, 2H, CH3CH3CH3), 1.83–1.92 (m, 2H,
CHCH2CH3), 2.53 (s, 2H, NH2), 2.69–2.82 (m, 1H,
CHNH2), 3.76–3.90 (m, 4H); 13C NMR (CDCl3): d=23.6
(CH2CH2CH2), 28.3 (CH3), 43.7 (NCH2CH2), 47.5 (CHNH2),
52.2 (NCH2CH), 79.3 [CCATHRE(UNG CH3)3], 154.8 (NCOO).
Biocatalysis
References
All kinetic resolutions were done at 378C, 600 rpm, in
sodium phosphate buffer (50 mM, pH 8), containing pyri-
doxal5 ’-phosphate (0.1 mM), racemic amine (5 mM) and
pyruvic acid (10 mM) unless otherwise indicated.
[1] J. P. Sanchez, J. M. Domagala, C. L. Heifetz, S. R.
Priebe, J. A. Sesnie, A. K. Trehan, J. Med. Chem. 1992,
35, 1764–1773.
[2] M. Muller, M. Soukup, World Patent WO2004013097,
2004.
Preparative-Scale Resolution of 1c
[3] M. W. Rowbottom, T. D. Vickers, B. Dyck, J. Grey, J.
Tamiya, M. Z. Zhang, M. Kiankarimi, D. P. Wu, W.
Dwight, W. S. Wade, D. Schwarz, C. E. Heise, A.
Madan, A. Fisher, R. Petroski, V. S. Goodfellow,
Bioorg. Med. Chem. Lett. 2006, 16, 4450–4457.
[4] W. Pfrengle, T. Pachur, T. Nicola, A. Duran, World
Patent WO2006048427A1, 2006.
[5] a) C. D. Beadle, M. J. Cases-Thomas, B. P. Clark, World
Patent WO2005000811, 2005; b) P. V. Fish, M. J. Fray,
D. J. Lovering, A. Stobie, F. Wakenhut, G. A. Whitlock,
World Patent WO2004110995, 2004; c) A. J. Allen,
D. K. Kelsey, World Patent WO2005020976, 2005.
[6] a) J. Einsiedel, C. Thomas, H. Hubner, P. Gmeiner,
Bioorg. Med. Chem. Lett. 2000, 10, 2041–2044; b) P.
Dicesare, D. Bouzard, M. Essiz, J. P. Jacquet, B. Le-
doussal, J. R. Kiechel, P. Remuzon, R. E. Kessler, J.
Fungtomc, J. Desiderio, J. Med. Chem. 1992, 35, 4205–
4213.
In a 500-mL round-bottom flask in a water bath, (R,S)-1c
(230 mg, 1.24 mmol) was dissolved in phosphate buffer
(122 mL, 50 mM, pH 8) and pyruvic acid (109 mg) was
added and the pH adjusted to 8. After heating to 378C, the
reaction was started by the addition of Ade-TA solution
(3.7 mL) and stirred with a magnetic stirrer bar. Conversion
and enantiomeric excess were analyzed as described above.
After 7 h, the pH of the mixture was adjusted to pH 3 with
HCl(5M), and the ketone 2c was extracted five times with
dichloromethane (75 mL). After the extraction, 2c was not
detectable in the residual aqueous phase. The pH was now
adjusted to pH 13, and the amine 1c was extracted four
times with dichloromethane. The solvents of the combined
extracts of 1c and 2c were evaporated and 1c (yield: 89 mg,
39%) and 2c (yield: 104 mg, 44%) were obtained. The struc-
tures of the compounds were confirmed by 1H and
13C NMR-spectroscopy.
1
[7] S. H. Moon, S. Lee, Synth. Commun. 1998, 28, 3919–
3926.
[8] a) H. Iding, B. Wirz, M. Rogers-Evans, Tetrahedron
2004, 60, 647–653; b) T. Ohno, H. Sato, T. Nozoe, Japa-
nese Patent JP 2002284761, 2002.
2c: H NMR (300 MHz, DMSO-d6): d=1.49 (s, 9H, CH3),
2.59 (t, 2H, J=7,8 Hz, COCH2), 3.75 (s, 2H, COCH2NCO2),
3.78 (t, 2H, J=7,8 Hz, CH2CH2NCO2); 13C NMR (DMSO-
d6): d=28.4 (CH3), 37.1 (CH2), 42.4 (CH2), 52.6 (CH2), 80.4
[C
ACHTREUNG(CH3)3], 154.4 (NCOO), 211.0 (CH2COCH2).
1
[9] K. Oohara, Y. Fujioka, Y. Ogura, Y. Nakada, Japanese
1c: H NMR (300 MHz, DMSO-d6): d=1.46 (s, 9H, CH3),
Patent, JP08239361, 1996.
1.6–1.7 (m, 1H, CHNH2CH2CH2), 1.98–2.1 (m, 1H,
CHNH2CH2CH2), 2.97–3.1 (m, 1H, CHNH2CH2NCO2), 3.3–
3.6 (m, 4H); 13C NMR (DMSO-d6): d=28.5 (CH3), 34.3+
34.8 (CHNH2CH2CH2), 43.9+44.3 (CH2CH2NCO2), 50.5+
51.4 (CHNH2), 54.1+54.4 (CHNH2CH2NCO2), 79.1 [C-
[10] a) S. Toshito, H. Kaisuke, Japanese Patent, JP9216866,
1997; b) H. Samuel, G. Meek, World Patent WO
2007075630, 2007.
[11] J.-S. Shin, B.-G. Kim, Biosci. Biotechnol. Biochem.
2001, 65, 1782–1788.
ACHTREUNG(CH3)3], 154.6 (NCO2).
[12] J.-S. Shin, B.-G. Kim, J. Org. Chem. 2002, 67, 2848–
2853.
[13] J.-S. Shin, H. Yun, J.-W. Jang, I. Park, B.-G. Kim, Appl.
Microbiol. Biotechnol. 2003, 61, 463–471.
Preparative-Scale Resolution of 1f
This was performed similar as described for 1a: 1-N-Boc-3-
aminopiperidine hydrochloride (0.25 mmol) and pyruvic
acid (0.25 mmol) were dissolved in phosphate buffer
(25 mL, 50 mM, pH 8), containing PLP (10 mM). After pH
adjustment to pH 8 and preincubation at 378C, the reaction
[14] H. Yun, S. Lim, B.-K. Cho, B.-G. Kim, Appl. Environ.
Microbiol. 2004, 70, 2529–2534.
[15] T. F. J. Lampe, H. M. R. Hoffmann, U. T. Bornscheuer,
Tetrahedron: Asymmetry 1996, 7, 2889–2900.
Adv. Synth. Catal. 2008, 350, 807 – 812
ꢀ 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
811